Allena Pharmaceuticals

Orally delivered non-systemic enzymes focusing on nephrologic and urologic conditions

Allena is developing protein therapies delivered orally to the gastrointestinal tract that reduce toxic metabolites without being absorbed into the bloodstream. The company’s lead candidate ALLN-177 is an orally administered recombinant oxalate degrading enzyme for the chronic management of hyperoxaluria and kidney stones. The drug is the first pharmacologic treatment to demonstrate a statistically significant reduction in urinary oxalate excretion, a positive finding for patients with hyperoxaluria.

IPO in 2017 (NASDAQ: ALNA)
Life Sciences
Newton, Massachusetts